The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 2001-02 phase III study comparing a first-line chemotherapy of LV5FU2 or FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly patients.
T. Aparicio
Honoraria - Merck; Novartis; Roche
J. Jouve
No relevant relationships to disclose
L. Teillet
No relevant relationships to disclose
D. Gargot
No relevant relationships to disclose
V. Le Brun Ly
No relevant relationships to disclose
J. Cretin
No relevant relationships to disclose
C. Locher
No relevant relationships to disclose
O. Bouche
Honoraria - Pfizer
G. Breysacher
No relevant relationships to disclose
J. Charneau
No relevant relationships to disclose
J. Seitz
No relevant relationships to disclose
M. Gasmi
No relevant relationships to disclose
F. Ricard
No relevant relationships to disclose
F. Subtil
No relevant relationships to disclose
E. Mitry
Honoraria - Pfizer